In the past few years, the medical net has been mentioned in recent years, because of the shortage of "lifesaving drugs" for various reasons.
▍ shortage of medicine is for our favorite stylemakers?
The author in the national drug supply security integrated management information platform with a "shortage" site search to find the information about the drug shortages since the site opened two years there will be information 112, visible shortage of drugs by the management departments at different levels of importance.
It is generally believed that the high cost, low profits, small audience is one of the reasons for the shortage of life-saving medicine, and universal, and there are some critics like protamine production raw material supply is seasonal, seasonal shortages may occur.
However, the author believes that there are two main reasons.
The price mechanism problem, the pharmaceutical factory produces the business intention not strong
At present, the pricing of drugs is mainly made by the national reform and development of national retail guidance prices of basic drugs, which can be used to maintain the reasonable profit of production enterprises and reduce the unreasonable marketing expenses. Combined with the deepening of health reform, drug control and drug price control measures are constantly being added, so drugs with low prices and high demand are often competitive. Even some pharmaceutical companies are bid for the bid, maliciously drive down the price, but also because the price is too low, there is no profit space, give up production.
Released recently, the anhui province medicine in platform on the investigation to verify the relevant drug purchase notice supply and production of inventory, and so on and so forth, the author listed on the shortage of 204 clinical drug discovery, including 66 drug was listed in the catalog of the first national cheap drugs.
In addition, the highest in drug retail price policy cancelled, the classification of the drug procurement, price paid, the hospital the second negotiation price formation mechanism such as background, the objective cause price signals is more unstable situation, does not favor the pharmaceutical production enterprise.
There is a lack of effective monitoring and early warning mechanism and list management system
China has not established a shortage of drug information collection and summary analysis mechanism. Although as early as 2011 with related professionals advocate advice based on big data applications of national drug supply security integrated management platform and a shortage of drug monitoring and early warning information system, but so far still not forming, shortage of relevant clinical drug monitoring and early warning and management system is impossible.
At present, most provinces and cities are fragmented, according to the medical institutions in the province of feedback preliminary list drugs, but in most cases did not take effective linkage mechanism, the effect is poorer.
▍ come true, anhui 204 shortage of drug information to track
27, medicine in anhui province platforms on the investigation to verify the relevant drug purchase inventory supply and production, and so on and so forth notice, requires all enterprises provided 204 listed drug management and inventory situation, anhui province pharmaceutical production enterprise need to fill in related production and factory cost, as to inform the specific content and 204 drug list and notice details see this platform on July 28, headlines article: 204 drugs, are required to publish ex-factory price.
Now for pharmaceutical circulation enterprises, is not a particularly big impact, but business agent situation truthfully fill in the can, but in the long term, in the relevant administrative department of the collection to the enterprise of production factory price will produce certain effect to the circulation enterprise, whether there is a random bonus is obvious.
But for these drug manufacturers, it's a dilemma. Want to inform oneself of medicine's factory price, want to show the card of the enterprise, equal to want beauty to report oneself "three round" size of the same drop!
However, there are also industry experts who believe that the terminal price of many shortages of medicines and the factory price of enterprises are upside down, which may not affect the enterprise.
▍ this 50 medicine will ex-factory price
Through comparison screening and sorting, I found that among the 204 medicines listed, 50 products were produced in anhui province, and the products involved in the treatment of various diseases. There are 56 production enterprises (list of specific enterprises), including many listed companies such as fengyuan pharmaceutical, anke biology, new and cheng etc.
All 50 products are in the national health insurance category, including 39 medical insurance products and 11 b products. In addition, five of the 50 products (note: acyclovir cream, chloramphenicol eye drops, sodium bicarbonate tablets, vitamin B2 and cimetidine tablets) are OTC products.
The basic information of specific varieties is as follows:
(note: data information is based on the data matching of 204 products and related products in anhui province for reference)
In any case, it is more resistant to the open price of the factory. Obviously, if the price of the factory is made public, the price of the drug will be greatly depressed, which may lead to some medicine being too cheap to make money, and no one will be willing to take delivery, and finally the enterprise will not be willing to produce.
Once the factory price of these 50 products is announced, the factory prices of the same products in other regions of the country will also be questioned or speculated. As the same drug, the factory price should not be too far off.
In fact, the relevant professional and related departments have been advocating the price information to track the price of the drug.
Due to the primary concern of nearly a year or two people fall on the "two votes", but in fact, as early as the beginning of last year, the prime minister li keqiang chaired a state council executive meeting also suggested that drugs ex-factory price information traceability mechanism should be established and this means that manufacturers are faced with the price monitoring stricter than in the past, this is much more than the so-called two votes.
In the face of the price traceability mechanism, manufacturers are mostly willing to cater to the two-ticket system in order to "comply" and reduce price risk.
In fact, after the establishment of the national development and reform commission in 2003, the drug price assessment center was set up in October 2005, and a number of large-scale drug price related investigations were carried out.
In April 2006, we asked to check and supplement the purchase price data of some drugs, and set up the price collection.
In May 2007, we asked for a comprehensive investigation of the cost of drugs, the price of the wholesale enterprises, the price of the winning bid and the retail price.
In 2010, the large-scale drug cost investigation was organized again.
In 2012, the general office of the national development and reform commission issued a notice on strengthening the price investigation and monitoring of drug factory prices, which required that pharmaceutical companies report factory prices from 1 September 2012.
After many rounds, the result is very little. Can anhui province make any gains this time? Wait and see.
The attached:
Anhui province needs to report the factory price related products and manufacturers
